Dennis Langer Sells 10,000 Shares of Myriad Genetics (MYGN) Stock

Myriad Genetics (NASDAQ:MYGN) Director Dennis Langer sold 10,000 shares of the stock in a transaction on Monday, May 21st. The stock was sold at an average price of $35.90, for a total transaction of $359,000.00. Following the transaction, the director now owns 49,743 shares in the company, valued at approximately $1,785,773.70. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Myriad Genetics traded up $0.28, hitting $35.68, during trading hours on Monday, according to MarketBeat Ratings. 468,689 shares of the stock were exchanged, compared to its average volume of 708,031. The company has a current ratio of 3.52, a quick ratio of 3.16 and a debt-to-equity ratio of 0.07. The company has a market cap of $2.47 billion, a P/E ratio of 33.98, a P/E/G ratio of 3.81 and a beta of 0.51. Myriad Genetics has a one year low of $19.75 and a one year high of $41.57.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, May 8th. The company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.04. Myriad Genetics had a net margin of 17.67% and a return on equity of 9.52%. The firm had revenue of $193.50 million during the quarter, compared to the consensus estimate of $188.22 million. During the same period in the prior year, the firm earned $0.27 EPS. The business’s revenue was down 1.7% on a year-over-year basis. equities research analysts forecast that Myriad Genetics will post 1.2 EPS for the current fiscal year.

A number of institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its holdings in Myriad Genetics by 59.5% in the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock valued at $136,000 after purchasing an additional 1,715 shares during the period. Meadow Creek Investment Management LLC boosted its holdings in Myriad Genetics by 19.4% in the 4th quarter. Meadow Creek Investment Management LLC now owns 11,322 shares of the company’s stock valued at $389,000 after purchasing an additional 1,836 shares during the period. Great West Life Assurance Co. Can boosted its holdings in Myriad Genetics by 2.0% in the 1st quarter. Great West Life Assurance Co. Can now owns 92,760 shares of the company’s stock valued at $2,740,000 after purchasing an additional 1,858 shares during the period. Meeder Asset Management Inc. boosted its holdings in Myriad Genetics by 58.3% in the 4th quarter. Meeder Asset Management Inc. now owns 5,210 shares of the company’s stock valued at $179,000 after purchasing an additional 1,918 shares during the period. Finally, Teachers Advisors LLC boosted its holdings in Myriad Genetics by 1.7% in the 4th quarter. Teachers Advisors LLC now owns 117,695 shares of the company’s stock valued at $4,042,000 after purchasing an additional 1,948 shares during the period.

MYGN has been the topic of several analyst reports. Barclays increased their price target on shares of Myriad Genetics from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research note on Monday, January 22nd. Goldman Sachs initiated coverage on shares of Myriad Genetics in a report on Monday, January 29th. They set a “sell” rating and a $32.00 price objective for the company. Morgan Stanley upped their price objective on shares of Myriad Genetics from $26.00 to $28.00 and gave the stock an “underweight” rating in a report on Wednesday, February 7th. Leerink Swann upped their price objective on shares of Myriad Genetics from $33.00 to $35.00 and gave the stock a “market perform” rating in a report on Wednesday, February 7th. Finally, BTIG Research set a $44.00 price objective on shares of Myriad Genetics and gave the stock a “buy” rating in a report on Wednesday, February 7th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $31.17.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BART, a DNA sequencing test for hereditary breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Insider Buying and Selling by Quarter for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply